 SHANGHAI and SAN FRANCISCO, Dec. 16, 2020 GLOBE NEWSWIRE -- Zai Lab Limiteds NASDAQ: ZLAB; HKEX: 9688 partner MacroGenics, Inc. Nasdaq: MGNX, a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration FDA has approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. MARGENZA is being further developed by MacroGenics for the treatment of advanced gastric cancer, with support by Zai Lab in Greater China. The approval in breast cancer in the U.S. was based on safety and efficacy results from the pivotal Phase 3 SOPHIA trial. 